Recent research examined if CAR T-cell infusion timing impacts success in Large B-cell Lymphoma (LBCL). Many oncologists have wondered if the human circadian rhythm influences the efficacy of cellular therapies. However, a large retrospective analysis now provides clarity on this administrative concern.

Furthermore, researchers evaluated 584 patients across six Australian medical centres. The study team specifically looked for links between the time of day a patient receives an infusion and their subsequent clinical outcome. Consequently, they adjusted the data for various clinical confounders to ensure accuracy. Although chronobiology is a significant factor in many physiological processes, the results showed no significant association with treatment success in this specific setting.

Moreover, the analysis revealed that toxicity rates and survival metrics remained stable regardless of the hour. Specifically, the risk of cytokine release syndrome or neurotoxicity did not vary by infusion time. Therefore, these findings suggest that the clinical impact of chronobiology is minimal for CAR T-cell therapy in LBCL. Similarly, clinicians can now feel more confident in scheduling these complex procedures based on hospital workflow and staff availability.

Clinical Perspectives on CAR T-cell infusion timing

Additionally, this evidence contrasts with some smaller studies that suggested a morning benefit for other immunotherapies. In contrast, the robust Australian data indicates that the therapeutic window for CAR T-cells is remarkably stable throughout the day. Although further prospective trials might refine these insights, current evidence supports flexible scheduling. Patient outcomes depend more on product characteristics and baseline disease factors than the clock.

Frequently Asked Questions

Does the time of day affect CAR T-cell therapy success?

No, this large-scale analysis of 584 patients found no association between the time of infusion and clinical outcomes in Large B-cell Lymphoma.

Can hospitals schedule CAR T-cell infusions flexibly?

Yes, the study suggests that scheduling can focus on operational efficiency because the time of administration does not significantly impact survival or safety.

Is chronobiology important in oncology?

While chronobiology affects many treatments, its impact on CAR T-cell therapy in LBCL appears to be minimal based on current retrospective data.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Dowling MR et al. Time of infusion does not significantly impact outcomes following CAR T-cell therapy in large B-cell lymphoma. Blood. 2026 Feb 17. doi: undefined. PMID: 41701973.

Shouval R et al. Time of Day of CAR T-Cell Infusion and Outcomes in Large B-Cell Lymphoma. Blood. 2026 Jan 5. doi: 10.1182/blood.2025026435.

Litvin R, Hill BT. Long-term outcomes and late toxicities of CAR T-cell therapy in large B-cell lymphoma. Expert Opin Biol Ther. 2026 Jan 27. doi: 10.1080/14712598.2026.2621889.